Ku Li-Jung Elizabeth, Tsai Jui-Hung, Chen Li-Jun, Yang Szu-Chun
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Centre for Healthy Brain Ageing, Discipline of Psychiatry and Mental Health, UNSW Medicine and Health, University of New South Wales, Sydney, Australia.
Ther Adv Med Oncol. 2025 Jan 3;17:17588359241312143. doi: 10.1177/17588359241312143. eCollection 2025.
Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ()-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated.
To study the cost-effectiveness of lazertinib as a first-line treatment for patients with -mutated advanced lung cancer.
A partitioned survival model-based cost-effectiveness analysis.
We conducted the economic analysis from the perspective of the healthcare sector with a lifetime horizon. Simulated patients were entered into the models upon the diagnosis of -mutated advanced lung cancer. Lazertinib was compared with gefitinib. The model inputs were derived from the trials (survival outcomes, incidence of adverse events (AEs), and subsequent therapies), National Health Insurance payments (costs of drugs and AEs), and hospital cohorts (utility values). Deterministic and probabilistic analyses were also conducted.
Applying the same daily price of osimertinib (US$110) to that of lazertinib, the incremental cost-effectiveness ratio of lazertinib versus gefitinib was US$93,792 per quality-adjusted life year (QALY). The cost of lazertinib was a major determinant. If the daily price of lazertinib could be reduced to US$75, lazertinib would become cost-effective at a willingness-to-pay (WTP) threshold of US$70,000 per QALY. Given the WTP threshold, the probability that lazertinib would be cost-effective was 0.7%.
Lazertinib is not a cost-effective first-line treatment for -mutated advanced lung cancer. Lowering prices enables cost-effectiveness.
拉泽替尼在表皮生长因子受体（EGFR）突变的晚期肺癌一线治疗中显示出与奥希替尼相似的疗效。然而，其成本效益尚未得到评估。
研究拉泽替尼作为EGFR突变晚期肺癌患者一线治疗的成本效益。
基于分区生存模型的成本效益分析。
我们从医疗保健部门的角度进行了为期一生的经济分析。模拟患者在被诊断为EGFR突变的晚期肺癌时进入模型。将拉泽替尼与吉非替尼进行比较。模型输入数据来自试验（生存结果、不良事件（AE）发生率和后续治疗）、国家医疗保险支付（药物和AE成本）以及医院队列（效用值）。还进行了确定性和概率分析。
将奥希替尼的每日价格（110美元）应用于拉泽替尼，拉泽替尼与吉非替尼相比的增量成本效益比为每质量调整生命年（QALY）93,792美元。拉泽替尼的成本是一个主要决定因素。如果拉泽替尼的每日价格可以降至75美元，那么在每QALY支付意愿（WTP）阈值为70,000美元的情况下，拉泽替尼将具有成本效益。考虑到WTP阈值，拉泽替尼具有成本效益的概率为0.7%。
拉泽替尼作为EGFR突变晚期肺癌的一线治疗方法不具有成本效益。降低价格可实现成本效益。
